デフォルト表紙
市場調査レポート
商品コード
1242323

クローン病(CD)治療の世界市場

Crohn's Disease (CD) Therapy

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
クローン病(CD)治療の世界市場
出版日: 2023年03月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

クローン病(CD)治療の世界市場は、2030年に159億米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に109億米ドルと推定されるクローン病(CD)治療の世界市場は、2030年までに159億米ドルに達すると予測され、2022年から2030年にかけてCAGR4.9%の成長率を示すと予測されます。本レポートで分析したセグメントの一つである抗TNF生物製剤は、CAGR5.8%を記録し、分析期間終了時には67億米ドルに達すると予測されます。パンデミック後の回復を考慮し、アミノサリチル酸塩分野の成長は、今後8年間のCAGRが2.8%に修正されました。

米国市場は32億米ドル、中国はCAGR4.5%で成長すると予測

米国のクローン病(CD)治療市場は、2022年に32億米ドルに達すると推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが4.5%となり、2030年には28億米ドルの市場規模に達すると予測されます。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ4.8%と3.7%の成長が予測されています。欧州では、ドイツがCAGR3.8%で成長すると予測されています。

調査対象企業の例

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co., Ltd.
  • ChemoCentryx, Inc.
  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP11374

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Crohn`s Disease (CD) Therapy Market to Reach $15.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Crohn`s Disease (CD) Therapy estimated at US$10.9 Billion in the year 2022, is projected to reach a revised size of US$15.9 Billion by 2030, growing at aCAGR of 4.9% over the period 2022-2030. Anti-TNF Biologics, one of the segments analyzed in the report, is projected to record 5.8% CAGR and reach US$6.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Aminosalicyates segment is readjusted to a revised 2.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $3.2 Billion, While China is Forecast to Grow at 4.5% CAGR

The Crohn`s Disease (CD) Therapy market in the U.S. is estimated at US$3.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 3.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co., Ltd.
  • ChemoCentryx, Inc.
  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Crohn`s Disease (CD) Therapy - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Crohn`s Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Crohn`s Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Aminosalicyates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Anti-TNF Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Anti-Integrin Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 22: World Crohn`s Disease (CD) Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • JAPAN
    • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • CHINA
    • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: China 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • EUROPE
    • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Crohn`s Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • FRANCE
    • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: France 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • GERMANY
    • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Crohn`s Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Rest of World Historic Review for Crohn`s Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Rest of World 16-Year Perspective for Crohn`s Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2023 & 2030

IV. COMPETITION